Top Tweets for #attruby
Attruby Emerges as a Compelling Alternative to Vyndamax in Cardiac Amyloidosis Treatment https://t.co/LnNYEWcDLH Read now at https://t.co/pYPVOJiweA
#PatientWorthy #VYNDAMAX #ATTR-COM #CardiacAmyloidosis #Attruby
Midday at #PCCS26
Join us for our lunchtime Industry Product Theater presented by @BridgeBio:
Extended Overview of #Attruby for ATTR-CM
π§ 12:45β1:45 PM (PT)
ποΈ Marcus A. Urey, MD | @UCSDHealth
*In-person + live-streamed.*
#JPM2026 Day 2!
π Free access to the JPM 2026 conference calendar in the comments ποΈ
$XBI SMID-cap biopharmas with commercial/marketed drugs presenting today:
$ACAD
$ALKS
$HRMY
$TGTX
$JAZZ
$ZLAB
$AMRX
$CHRS
***
$BBIO #JPM26 #ATTRUBY key nuggets. Momentum building!
See @semodough for details from yesterdayβs presentation. π
$BBIO #JPM26 #ATTRUBY KEY NUGGETS solid performance appears to be driven by an acceleration in momentum of new patient adds (~1,370 new Rxs between last Oct 29th data-cut and Dec 31st = >150 new patients added per week (vs previous updates in the ~120 new Rx per week range)). >25% market share of the TTR-CM treatment naive population (up from ~20% in 3Q25)
$BBIO #JPM26 #ATTRUBY KEY NUGGETS solid performance appears to be driven by an acceleration in momentum of new patient adds (~1,370 new Rxs between last Oct 29th data-cut and Dec 31st = >150 new patients added per week (vs previous updates in the ~120 new Rx per week range)). >25% market share of the TTR-CM treatment naive population (up from ~20% in 3Q25)
$BBIO share price reaction is a clear overreaction. #Attruby growth ($71.5M in Q2 vs. the first quarter of launch: sales of $36.7M) just impressive. The ongoing positive feedback could prove to be very valuable in the long term and set $BBIO apart from competition. $ALNY $PFE
$BBIO Attruby launch exceeds all expectations. As I wrote in January: The company could become the next $VRNA. Both companies with top Q1 figures. There is more to come.
Next: $BPMC earnings on Thursday.
More and more analysts realize the sales potential for #Attruby and the late stage pipeline potential of $BBIO. Today Jefferies initiated the shares of the rare disease company with a "Buy" and PT $70. As I wrote in January: strong launch can lead to a "massive revaluation".
The market will quickly realize that $BBIO has a really good chance of Attruby becoming a clear blockbuster. We have seen with $VRNA how quickly a strong launch can lead to a massive revaluation. $ALNY $PFE
The market will quickly realize that $BBIO has a really good chance of Attruby becoming a clear blockbuster. We have seen with $VRNA how quickly a strong launch can lead to a massive revaluation. $ALNY $PFE
$BBIO $41 - new 52 week high. Needs to break 2023 high, then more room to run. Q2 sales of #Attruby should be really good. As I said: #BridgeBio could be the next $VRNA. π
$BBIO Attruby launch exceeds all expectations. As I wrote in January: The company could become the next $VRNA. Both companies with top Q1 figures. There is more to come.
Next: $BPMC earnings on Thursday.
$BBIO πͺπ now almost $7.5B worth. 50% since post. More to come, #Attruby launch really strong and multiple other blockbuster opportunities.
$BBIO is only $5B worth. #Attruby alone could generate peak sales of $3B - depending on the sales development of the competitors $ALNY and $PFE. Just the #Acoramidis asset justifies the current valuation. Great pipeline on top.
$BBIO to report fourth quarter and full year 2024 financial results and business update tomorrow. I expect a strong launch of #Attruby. Maybe the start of the "massive revaluation" like $VRNA after #Ohtuvayre launch? We'll see. $ALNY $PFE $BAYN https://t.co/lgU6VmBqBn
The market will quickly realize that $BBIO has a really good chance of Attruby becoming a clear blockbuster. We have seen with $VRNA how quickly a strong launch can lead to a massive revaluation. $ALNY $PFE
$BBIO back to the $30s. Huge potential, see below. First #Attruby sales indications promising. "Looking Ahead: Attruby Delivers Outstanding Results in Patients with Poor Prognosis" https://t.co/IH5cb9wk0B
$BBIO is only $5B worth. #Attruby alone could generate peak sales of $3B - depending on the sales development of the competitors $ALNY and $PFE. Just the #Acoramidis asset justifies the current valuation. Great pipeline on top.
$BBIO Mizuho comment ("Buy", PT $53) after FDA approval of #Attruby - "stock should be $30+ on relief" - "best case indication statement". Shares up 8% on Friday after my post - $30+ possible next week. Patience. π $PFE $ALNY
$BBIO is only $5B worth. #Attruby alone could generate peak sales of $3B - depending on the sales development of the competitors $ALNY and $PFE. Just the #Acoramidis asset justifies the current valuation. Great pipeline on top.
$BBIO is only $5B worth. #Attruby alone could generate peak sales of $3B - depending on the sales development of the competitors $ALNY and $PFE. Just the #Acoramidis asset justifies the current valuation. Great pipeline on top.
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
240.1M followers
Barack Obama
@barackobama
119.3M followers
Donald J. Trump
@realdonaldtrump
111.6M followers
Cristiano Ronaldo
@cristiano
108.9M followers
Narendra Modi
@narendramodi
107M followers
Rihanna
@rihanna
97.3M followers
NASA
@nasa
92.1M followers
Justin Bieber
@justinbieber
90.6M followers
KATY PERRY
@katyperry
86.8M followers
Taylor Swift
@taylorswift13
80.6M followers
Lady Gaga
@ladygaga
72.1M followers
Kim Kardashian
@kimkardashian
69.4M followers
YouTube
@youtube
68.6M followers
Virat Kohli
@imvkohli
68.5M followers
Bill Gates
@billgates
63.4M followers
The Ellen Show
@theellenshow
62.5M followers
CNN
@cnn
61.9M followers
Neymar Jr
@neymarjr
61.1M followers
X
@x
60.9M followers
Selena Gomez
@selenagomez
59.9M followers